Get in Touch

Contact us for more information about Grifols

Call us

1-888-474-3657

Write to us

Grifols
79 TW Alexander Dr
4101 Research Commons
Research Triangle Park,
NC 27709

Fill out the form below and get in contact with us

All fields are required unless otherwise stated

First Name

Last Name

Email Address

Phone Number (Optional)

Comments

0 characters left

Data Protection Information
The Grifols' group company to which you submit the request, as data controller, will process your personal data to manage your requests of information, suggestions and/or queries. The legal basis is Grifols' legitimate interest. Your data may be shared with Grifols' group companies and other third parties. You have the right to access, rectify and erase, as well as any other rights detailed in the additional information. For additional information on personal data protection check here.

recaptcha-check Required

By clicking the button below, I declare being informed that my data is being used as described in the data protection information.

Important Safety Information for HyperRAB® (rabies immune globulin [human])

Indication and Usage

HyperRAB^® (rabies immune globulin [human]) is indicated for postexposure prophylaxis, along with rabies vaccine, for all persons suspected of exposure to rabies.

Limitations of Use

Persons who have been previously immunized with rabies vaccine and have a confirmed adequate rabies antibody titer should receive only vaccine.

For unvaccinated persons, the combination of HyperRAB and vaccine is recommended for both bite and nonbite exposures regardless of the time interval between exposure and initiation of postexposure prophylaxis.

Beyond 7 days (after the first vaccine dose), HyperRAB is not indicated since an antibody response to vaccine is presumed to have occurred.

Important Safety Information

For infiltration and intramuscular use only.

Severe hypersensitivity reactions may occur with HyperRAB. Patients with a history of prior systemic allergic reactions to human immunoglobulin preparations are at a greater risk of developing severe hypersensitivity and anaphylactic reactions. Have epinephrine available for treatment of acute allergic symptoms, should they occur.

HyperRAB is made from human blood and may carry a risk of transmitting infectious agents, eg, viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent, and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent.

The most common adverse reactions in >5% of subjects during clinical trials were injection-site pain, headache, injection-site nodule, abdominal pain, diarrhea, flatulence, nasal congestion, and oropharyngeal pain.

Do not administer repeated doses of HyperRAB once vaccine treatment has been initiated as this could prevent the full expression of active immunity expected from the rabies vaccine.

Other antibodies in the HyperRAB preparation may interfere with the response to live vaccines such as measles, mumps, polio, or rubella. Defer immunization with live vaccines for 4 months after HyperRAB administration.

Please see full Prescribing Information for HyperRAB.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.